



## Priority-driven Collaborative Cancer Research Scheme 2012

Cancer Australia; Australian Rotary Health; Cancer Council Australia; Cancer Council New South Wales; Cure Cancer Australia Foundation; National Breast Cancer Foundation; and Prostate Cancer Foundation of Australia, are pleased to announce applicants who have been recommended for funding in the 2012 Round of the Priority-driven Collaborative Cancer Research Scheme.

### **Beaumont, Kimberley**

Centenary Institute of Cancer Medicine and Cell Biology  
*The role of Rab27a and Rab5a in melanoma phenotype switching*  
Funded by Cure Cancer Australia Foundation

### **Bowden, Nikola**

University of Newcastle  
*Investigation of the nucleotide excision repair pathway for melanoma biomarkers*  
Funded by Cure Cancer Australia Foundation

### **Buchanan, Daniel**

Queensland Institute of Medical Research  
*Germline copy number variants are genetic risk factors for familial colorectal cancer*  
Co-funded by Cure Cancer Australia Foundation and Cancer Australia

### **Butler, Lisa**

University of Adelaide  
*A pharmacodynamic study of the heat shock protein 90 (Hsp90) inhibitor, AUY922, in high-risk, localised prostate cancer*  
Co-funded by Prostate Cancer Foundation of Australia and Cancer Australia

### **Colvin, Emily**

Kolling Institute of Medical Research  
*Investigating the tumour-promoting phenotype of cancer-associated fibroblasts in serous epithelial ovarian cancer*  
Co-funded by Cure Cancer Australia Foundation and Cancer Australia

### **Friedlander, Michael**

The Prince of Wales Hospital  
*ICON8: An international multi-stage randomised phase III trial of dose-fractionated chemotherapy compared to standard three-weekly chemotherapy for women with newly diagnosed epithelial ovarian cancer*  
Co-funded by Cancer Council Australia and Cancer Australia– gynaecological cancers program

### **Georgy Smitha**

Monash University  
*The role of mammalian transcription factor Grainyhead-like 3 in oesophageal cancer*  
Funded by Cure Cancer Australia Foundation

**Grimison, Peter**

University of Sydney

*Accelerating first-line chemotherapy to improve cure rates for advanced germ cell tumours: an Australian-led, international randomised trial*

Funded by Cancer Australia

**Hayne, Dickon**

University of Western Australia

*Adding mitomycin C to intravesical BCG for high-risk, non-muscle-invasive bladder cancer: a randomised phase 3 trial*

Funded by Cancer Australia

**Hong, Angela**

University of Sydney

*Improving the outcomes of oropharyngeal cancer: specific human papillomavirus oncoproteins and p53 mutations as modifying factors*

Funded by Cure Cancer Australia Foundation

**Hutchinson, Andrew**

University of Technology Sydney

*Molecular characterisation and evaluation of neutral sphingomyelinase 2 as a novel target in multiple myeloma*

Co-funded by Cure Cancer Australia Foundation and Cancer Australia

**Janda, Monika**

Queensland University of Technology

*Mirena ± Weight Loss to treat early Endometrial Cancer: (MAxWEL Trial)*

Funded by Cancer Australia– gynaecological cancers program

**Jayachandran, Aparna**

Ludwig Institute for Cancer Research

*Hitting a moving target – overcoming invasion and resistance mechanisms by understanding melanoma plasticity using a combination of pre-clinical models*

Funded by Cure Cancer Australia Foundation

**Jin, Feng**

The Kirby Institute

*Testing of biomarkers of human papillomavirus on anal cytology in homosexual men to predict the presence of high-grade anal intraepithelial neoplasia and its progression and persistence*

Funded by Cure Cancer Australia Foundation

**Lucas, Robyn**

Australian National University

*Equivalence of sun exposure and vitamin D supplementation in vitamin D insufficiency*

Funded by Cancer Australia

**Micklethwaite, Kenneth**

Westmead Hospital

*Production of off the shelf T-cells expressing a non-MHC restricted CD19 specific chimeric antigen receptor for use in a Phase I study of T-cell therapy of relapsed and refractory B cell malignancies (UNI-T Study)*

Co-funded by Cure Cancer Australia Foundation and Cancer Australia

**Mielke, Lisa**

Walter and Eliza Hall Institute of Medical Research  
*Innate immune cell protection and colon cancer*  
Co-funded by Cure Cancer Australia Foundation and Cancer Australia

**Morton, Rachael**

University of Sydney  
*The cost-effectiveness of adjuvant whole brain radiotherapy for melanoma brain metastases: a trial-based and modelled economic evaluation*  
Funded by Cancer Australia

**Moujalled, Donia**

Walter and Eliza Hall Institute of Medical Research  
*Mechanisms of RIPK3 activation by TNFR1*  
Funded by Cure Cancer Australia Foundation

**Nunez de Costa, Patricia**

Austin Hospital  
*The role of kinin receptors in liver regeneration and growth of colorectal liver metastases*  
Funded by Cure Cancer Australia Foundation

**O'Reilly, Lorraine**

Walter and Eliza Hall Institute of Medical Research  
*Understanding the role of NF- $\kappa$  B in the progression of gastric adenocarcinomas and assessment of new therapies*  
Funded by Cancer Council NSW

**Pangon, Laurent**

Garvan Institute of Medical Research  
*Characterising a new mode of regulation of the beta-catenin pathway in colorectal cancer*  
Funded by Cure Cancer Australia Foundation

**Payne, Richard**

University of Sydney  
*Preparation and evaluation of synthetic self-adjuvanting cancer vaccine candidates*  
Funded by Cure Cancer Australia Foundation

**Pearson, Sallie**

University of Sydney  
*The use and impact of high cost targeted cancer medicines: theory and reality*  
Co-funded by National Breast Cancer Foundation and Cancer Australia

**Perrow, Kara**

University of Wollongong  
*Development of bifunctional anti-uPA/Anti-HER-2 lipidic nanoparticles to target advanced breast cancer*  
Funded by Cure Cancer Australia Foundation

**Price, Timothy**

The Queen Elizabeth Hospital  
*PETACC-6: Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer*  
Funded by Cancer Australia

**Pritchard, Antonia**

Queensland Institute of Medical Research  
*Identification of novel tumour epitopes as targets for immunotherapy*  
Funded by Cure Cancer Australia Foundation

**Risbridger, Gail**

Monash University  
*Defining epigenetic changes in prostate cancer stroma*  
Funded by Cancer Australia

**Salmon, Jessica**

Peter MacCallum Cancer Centre  
*Epigenetic therapies for the treatment of acute myeloid leukaemia*  
Funded by Cure Cancer Australia Foundation

**Schofield, Penny**

Peter MacCallum Cancer Centre  
*Solving Unknown Primary cancer – SUPER*  
Funded by Cancer Australia

**Sjoquist, Katrin**

University of Sydney  
*A Phase II study to evaluate the safety and potential benefit of intraperitoneal (IP) bevacizumab to control symptomatic malignant ascites in patients with chemotherapy resistant ovarian cancers: REZOLVE (ANZGOG-1101)*  
Funded by Cancer Australia

**Southey, Melissa**

University of Melbourne  
*High risk genes for lobular breast cancer*  
Co-funded by National Breast Cancer Foundation and Cancer Australia

**Tilley, Wayne**

University of Adelaide  
*Mechanism and targeting of castration-resistant prostate cancer*  
Co-funded by Australian Rotary Health, Prostate Cancer Foundation of Australia and Cancer Australia

**Tilley, Wayne**

University of Adelaide  
*Targeting the androgen receptor in triple negative breast cancer*  
Co-funded by National Breast Cancer Foundation and Cancer Australia

**Tomlinson, Christopher**

Children's Medical Research Institute  
*Investigating the mechanism of action of the cancer-associated enzyme telomerase using disease linked telomerase mutants*  
Co-funded by Cure Cancer Australia Foundation and Cancer Australia

**Ugalde, Anna**

Peter MacCallum Cancer Centre  
*The role and contribution of Australia's cancer caregivers*  
Funded by Cure Cancer Australia Foundation

**Waithman, Jason**

Telethon Institute for Child Health Research  
*Induction of adaptive immunity during melanoma*  
Funded by Cure Cancer Australia Foundation

**Weigmans, Adrian**

Queensland Institute of Medical Research  
*RAD51 overexpression regulates pro-metastatic gene expression profiles of aggressive metastatic triple negative breast cancer*  
Co-funded by Cure Cancer Australia Foundation and Cancer Australia

**Zheng, Yu**

Garvan Institute of Medical Research  
*Mechanisms of self-amplification and tumour growth in breast and prostate cancer metastases to bone*  
Funded by Cure Cancer Australia Foundation